There is evidence that blocking the PD-1 pathway alone or in combination with anti-CTLA-4 can produce antitumor effects in NSCLC or SCLC, and combination therapy seems to provide a larger tumor response [62], but treatment-related toxicity is also increased. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.